Zepbound vs Ozempic: FDA Indications, Trial Findings

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

This is an independent editorial comparison. PlexusDx has no commercial relationship with the manufacturers of the products reviewed.

Ozempic and Zepbound are two widely-discussed names in the GLP-1 receptor agonist landscape as of April 2026. They share a drug class but differ in active ingredient, FDA-approved indications, dosing format, clinical trial populations, and cost structure. This article compares the two head-to-head on mechanism, evidence, safety, and access — plus the upstream genetic variables that apply regardless of which compound a provider ultimately prescribes.

Side-by-side mechanism

Ozempic (semaglutide, Novo Nordisk) is a GLP-1 pathway compound. Zepbound (tirzepatide, Eli Lilly) is a GIP/GLP-1 dual agonist. Tirzepatide is a GIP/GLP-1 dual agonist; semaglutide, liraglutide, and dulaglutide are GLP-1-selective receptor agonists; retatrutide is an investigational GLP-1/GIP/glucagon triple agonist not FDA-approved as of April 2026. All engage the GLP-1 receptor and modulate gastric emptying, post-meal glucose excursions, and satiety signaling.

FDA status and approved indications

FDA approval for each product depends on indication: Ozempic (semaglutide) is FDA-approved for type 2 diabetes (2017); Wegovy (semaglutide 2.4 mg) for chronic weight management (2021); Rybelsus (oral semaglutide) for type 2 diabetes (2019); Mounjaro (tirzepatide) for type 2 diabetes (2022); Zepbound (tirzepatide) for chronic weight management (2023) and obstructive sleep apnea in adults with obesity (2024, SURMOUNT-OSA); Trulicity (dulaglutide) for type 2 diabetes (2014); Victoza (liraglutide) for type 2 diabetes (2010). Retatrutide is investigational and not FDA-approved.

Evidence and clinical trials

Key trial programs: STEP (semaglutide for weight management), SUSTAIN and SELECT (semaglutide for diabetes and cardiovascular outcomes), SURMOUNT and SURPASS (tirzepatide for weight management and diabetes), SURMOUNT-OSA (tirzepatide for sleep apnea), LEAD and LEADER (liraglutide for diabetes and cardiovascular outcomes), AWARD (dulaglutide). Head-to-head data exists for some pairings (SUSTAIN 7 compared semaglutide 1 mg to dulaglutide 1.5 mg; SURPASS-2 compared tirzepatide to semaglutide 1 mg in type 2 diabetes). Trial populations, doses, and primary endpoints differ — the cleanest read is per-trial, not per-class sweeping claims.

Side effects and safety

All FDA-approved GLP-1 receptor agonists and GIP/GLP-1 dual agonists carry the class boxed warning for thyroid C-cell tumor risk observed in rodent studies, and all are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Most common side effects are gastrointestinal (nausea, vomiting, diarrhea, constipation), typically most pronounced during dose escalation. Rare serious events include pancreatitis, gallbladder events, and acute kidney injury in the context of dehydration.

Cost and access

As of April 2026, list prices for the FDA-approved brands range roughly $815–$1,620 per month at U.S. list price (manufacturer published pricing). Out-of-pocket cost depends heavily on insurance coverage, the FDA indication on the prescription, manufacturer savings card eligibility, and compounded-alternative availability through licensed compounding pathways.

The overlapping genetic variables

Whichever compound a clinician ultimately prescribes, the upstream genetic architecture is shared. Variants in FTO (the fat-mass and obesity-associated gene — common variants influence appetite regulation and adiposity set-point), GLP1R (the gene encoding the GLP-1 receptor that every GLP-1 pathway compound engages), MC4R (a melanocortin receptor gene central to energy balance), and TCF7L2 (a transcription factor linked to glucose homeostasis and GLP-1 secretion) shape the baseline metabolic terrain on which any GLP-1 pathway compound has to work. These variants are pathway-level; they do not predict response to any one compound, but they do map the biology a clinician is prescribing into.

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — available as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. What sets the PlexusDx approach apart is the upstream genetic context. Before starting any GLP-1 pathway protocol, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, and 150+ genetic insights — including variants in FTO, GLP1R, MC4R, TCF7L2 that shape your baseline GLP-1, appetite-regulation, and energy-balance biology. Knowing that genetic profile alongside the protocol itself is the test before you invest approach — turning guesswork into an informed conversation with your healthcare provider.

Disclaimer: This article is educational. PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — this article covers the mechanism, evidence, and genetic context that informs any decision to use them. PlexusDx does not sell, prescribe, or recommend any other therapeutic peptide in the GLP-1 category beyond semaglutide and tirzepatide (including dulaglutide, liraglutide, retatrutide, cagrilintide, and related compounds). The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways — it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Start with the biology. Take the Precision Peptide Genetic Test, or explore the Weight Management Protocols.

Frequently Asked Questions

How does Ozempic differ from Zepbound mechanically?

Ozempic (semaglutide) and Zepbound (tirzepatide) differ in receptor engagement: tirzepatide is a GIP/GLP-1 dual agonist, while semaglutide, dulaglutide, and liraglutide are GLP-1-selective. Retatrutide is an investigational triple agonist. Half-life and dosing frequency also differ across these molecules, which shapes how each is administered.

Which is more effective for weight loss?

Head-to-head data in weight management is limited and trial-specific. SURPASS-2 compared tirzepatide to semaglutide 1 mg in type 2 diabetes and showed larger mean weight reduction with tirzepatide in that trial; weight-management trials used different endpoints. Individual response varies — discuss with a healthcare provider.

Can genetic testing predict which is right for me?

No. The Precision Peptide Genetic Test does not predict response to Ozempic, Zepbound, or any specific medication. It analyzes pathway-level variants in FTO, GLP1R, MC4R, and TCF7L2 that shape baseline GLP-1 and energy-balance biology — the upstream variable that applies across both compounds.

Are the side effects different between them?

Side-effect profiles are broadly similar across the class: GI symptoms are most common and typically most pronounced during dose escalation. All carry the class-wide boxed warning for thyroid C-cell tumor risk observed in rodent studies. Rare serious events include pancreatitis and gallbladder disease — discuss full history with a provider.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Zepbound vs Ozempic: FDA Indications, Trial Findings, Tolerability

Ozempic (semaglutide) and Zepbound (tirzepatide) are widely compared GLP-1 pathway compounds. This head-to-head covers mechanism, FDA status, trial evidence, boxed-warning safety, April 2026 list pricing, and the FTO, GLP1R, MC4R, and TCF7L2 variants that shape baseline GLP-1 biology.